FY2020 Earnings Forecast for Heron Therapeutics, Inc. (HRTX) Issued By Oppenheimer Holdings
Heron Therapeutics, Inc. (NASDAQ:HRTX) – Oppenheimer Holdings cut their FY2020 earnings estimates for Heron Therapeutics in a research report issued on Friday. Oppenheimer Holdings analyst D. Archila now forecasts that the biotechnology company will post earnings of $1.45 per share for the year, down from their prior forecast of $1.46. Oppenheimer Holdings has a “Buy” rating and a $27.00 price objective on the stock. Oppenheimer Holdings also issued estimates for Heron Therapeutics’ FY2021 earnings at $3.29 EPS.
A number of other brokerages also recently issued reports on HRTX. Zacks Investment Research upgraded Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 8th. Noble Financial restated a “buy” rating and set a $24.00 price objective on shares of Heron Therapeutics in a research report on Friday, October 6th. BidaskClub upgraded Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 26th. Cowen and Company set a $40.00 price objective on Heron Therapeutics and gave the company a “buy” rating in a research report on Thursday, August 3rd. Finally, Aegis restated a “buy” rating and set a $33.00 price objective on shares of Heron Therapeutics in a research report on Tuesday, July 18th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $28.36.
ILLEGAL ACTIVITY NOTICE: “FY2020 Earnings Forecast for Heron Therapeutics, Inc. (HRTX) Issued By Oppenheimer Holdings” was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/fy2020-earnings-forecast-for-heron-therapeutics-inc-hrtx-issued-by-oppenheimer-holdings/1700054.html.
Shares of Heron Therapeutics (HRTX) traded down $1.00 during mid-day trading on Monday, reaching $16.35. The company’s stock had a trading volume of 2,357,100 shares, compared to its average volume of 817,824. Heron Therapeutics has a fifty-two week low of $12.21 and a fifty-two week high of $20.85. The company has a current ratio of 2.12, a quick ratio of 2.02 and a debt-to-equity ratio of 0.62.
Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Monday, November 6th. The biotechnology company reported ($0.77) EPS for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.10. The company had revenue of $8.57 million for the quarter, compared to the consensus estimate of $8.12 million. Heron Therapeutics had a negative return on equity of 385.11% and a negative net margin of 831.89%.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Legal & General Group Plc grew its stake in Heron Therapeutics by 13.9% in the first quarter. Legal & General Group Plc now owns 8,971 shares of the biotechnology company’s stock worth $136,000 after purchasing an additional 1,098 shares in the last quarter. Quantbot Technologies LP grew its stake in Heron Therapeutics by 2,619.6% in the second quarter. Quantbot Technologies LP now owns 12,483 shares of the biotechnology company’s stock worth $172,000 after purchasing an additional 12,024 shares in the last quarter. Trexquant Investment LP bought a new position in Heron Therapeutics in the third quarter worth approximately $206,000. HighTower Advisors LLC grew its stake in Heron Therapeutics by 11.4% in the second quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock worth $231,000 after purchasing an additional 1,700 shares in the last quarter. Finally, Tudor Investment Corp ET AL bought a new position in Heron Therapeutics in the first quarter worth approximately $253,000.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.